『药品』精准药物助力多学科合作,NSCLC脑转移规范化诊疗新趋势 | CNS学院报道( 五 )


[7]Xu Q, Zhou F, Liu H, et al. Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs. J Thorac Oncol. 2018;13(9):1383–1392. doi:10.1016/j.jtho.2018.05.019
[8]Preusser M, Winkler F, Valiente M, et al. Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion. ESMO Open. 2018;3(1):e000262. Published 2018 Jan 26. doi:10.1136/esmoopen-2017-000262
[9]Cheng H, Perez-Soler R. Leptomeningeal metastases in non-small-cell lung cancer. Lancet Oncol. 2018;19(1):e43–e55. doi:10.1016/S1470-2045(17)30689-7
[10]Ballard P, Yates JW, Yang Z, et al. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clin Cancer Res. 2016;22(20):5130–5140. doi:10.1158/1078-0432.CCR-16-0399
[11]根据会议(CNS线上学院)内容整理 。
『药品』精准药物助力多学科合作,NSCLC脑转移规范化诊疗新趋势 | CNS学院报道
本文插图


推荐阅读